Teva制药公司为从Perseris转至UZEDY的精神分裂症患者提供了类似的药理动力学特征。 Teva Pharmaceuticals presents comparable pharmacokinetic profiles for schizophrenia patients switching from Perseris to UZEDY.

Teva制药公司在欧洲国家进步大会上公布了有关精神分裂症患者从Perseris向UZEDY过渡的新数据,UZEDY是可注射抗抑郁素的长释放注射剂。 Teva Pharmaceuticals has released new data at the ECNP Congress regarding the transition of schizophrenia patients from Perseris to UZEDY, an extended-release injectable of risperidone. 调查结果显示,在最后一次Perseris剂量后四周内改用UZEDY,可得出类似的药理动力学特征。 The findings suggest that switching to UZEDY four weeks after the last Perseris dose results in a comparable pharmacokinetic profile. 这项研究旨在加强治疗战略,强调病人偏好和在转换决定时可容忍等因素的重要性。 This research aims to enhance treatment strategies, highlighting the importance of factors like patient preferences and tolerability in switching decisions.